Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms EQUATOR
  • Sponsors Galapagos NV

    • Most Recent Events

    • 09 Nov 2021 Results of whole-blood RNA-Seq data analysis evaluatingthe impact of Filgotinib on gene expression and biological pathways, presented at the ACR Convergence 2021
    • 05 Jun 2021 Results of a post-hoc analysis from EQUATOR and EQUATOR 2 (up to OLE week 100) assessing effect of Filgotinib on individual PASDAS socre components and association between PASDAS disease activity levels presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 05 Jun 2021 Results post-hoc analysis from clinical studies: EQUATOR and EQUATOR 2 assessing patient-level correlation between changes over time in three PsA clinical disease domains of skin, joint and enthesitis presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top